Form 4 for CALC CalciMedica, Inc.
Accepted 2023-03-22 00:00:00 ET · period of report 2023-03-20 · accession 0001209191-23-020684 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2023-03-22 | 2023-03-20 | CALC | MIDDLETON FRED A | Dir, 10% | A - Grant | — | +1.65M | 8,884 | New | — |
| D | 2023-03-22 | 2023-03-20 | CALC | MIDDLETON FRED A | Dir, 10% | A - Grant | — | +5,760 | 5,760 | New | — |
| DMI | 2023-03-22 | 2023-03-20 | CALC | MIDDLETON FRED A | Dir, 10% | A - Grant | — | +74.4K | 15.4K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-20 | A | A | 703,388 | — | 703,388 | I By Sanderling Venture Partners VI, L.P. | — | — | (F1) Received in exchange for 24,423,158 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. (F2) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI, LP ("SVP VI, LP", together with Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 2 | Common | Common Stock | 2023-03-20 | A | A | 582,757 | — | 582,757 | I By Sanderling Venture Partners VI Co-Investment Fund, L.P. | — | — | (F3) Received in exchange for 20,234,606 shares of the common stock of CalciMedica pursuant to the Merger Agreement. (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 3 | Common | Common Stock | 2023-03-20 | A | A | 17,682 | — | 17,682 | I By Sanderling Ventures Management VI | — | — | (F5) Received in exchange for 613,943 shares of the common stock of CalciMedica pursuant to the Merger Agreement. (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 4 | Common | Common Stock | 2023-03-20 | A | A | 7,456 | — | 7,456 | I By Sanderling VI Beteligungs GmbH & Co KG | — | — | (F6) Received in exchange for 258,883 shares of the common stock of CalciMedica pursuant to the Merger Agreement. (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 5 | Common | Common Stock | 2023-03-20 | A | A | 8,176 | — | 8,176 | I By Golden Triangle Ventures, LLC | — | — | (F14) Received in exchange for 283,866 shares of the common stock of CalciMedica pursuant to the Merger Agreement. (F15) The Reporting Person is a managing member of Golden Triangle Ventures LLC and may be deemed to beneficially own the securities of the Issuer held by Golden Triangle Ventures LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 6 | Common | Common Stock | 2023-03-20 | A | A | 256,852 | — | 256,852 | I By Sanderling Ventures VII, L.P. | — | — | (F8) Received in exchange for 8,918,437 shares of the common stock of CalciMedica pursuant to the Merger Agreement. (F9) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the "Sanderling VII Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 7 | Common | Common Stock | 2023-03-20 | A | A | 14,425 | — | 14,425 | I By Sanderling Ventures VII Annex Fund, L.P. | — | — | (F10) Received in exchange for 500,854 shares of the common stock of CalciMedica pursuant to the Merger Agreement. (F11) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 8 | Common | Common Stock | 2023-03-20 | A | A | 47,052 | — | 47,052 | I By Sanderling Ventures VII (Canada), L.P. | — | — | (F12) Received in exchange for 1,633,699 shares of the common stock of CalciMedica pursuant to the Merger Agreement. (F11) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 9 | Common | Common Stock | 2023-03-20 | A | A | 1,548 | — | 1,548 | I By Sanderling Ventures Management VII | — | — | (F13) Received in exchange for 53,733 shares of the common stock of CalciMedica pursuant to the Merger Agreement. (F11) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 10 | Common | Common Stock | 2023-03-20 | A | A | 8,884 | — | 8,884 | I By Sanderling VI Limited Partnership | — | — | (F7) Received in exchange for 308,455 shares of the common stock of CalciMedica pursuant to the Merger Agreement. (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 11 | Derivative | Warrant | 2023-03-20 | A | A | 5,760 | — | 5,760 | D By Sanderling Venture Partners VI, LP | $10.42 · — to 2032-10-24 | 5,760 Common Stock | (F17) Received in exchange for a warrant to purchase 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 12 | Derivative | Warrant | 2023-03-20 | A | A | 113 | — | 113 | I By Sanderling Ventures Management VII | $27.94 · — to 2026-03-04 | 113 Common Stock | (F32) Received in exchange for a warrant to purchase 3,915 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 13 | Derivative | Warrant | 2023-03-20 | A | A | 840 | — | 840 | I By Sanderling Ventures Management VII | $27.94 · — to 2026-06-25 | 840 Common Stock | (F31) Received in exchange for a warrant to purchase 29,139 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 14 | Derivative | Warrant | 2023-03-20 | A | A | 569 | — | 569 | I By Sanderling Ventures VII Annex Fund, L.P. | $27.94 · — to 2026-03-04 | 569 Common Stock | (F30) Received in exchange for a warrant to purchase 19,754 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 15 | Derivative | Warrant | 2023-03-20 | A | A | 3,249 | — | 3,249 | I By Sanderling Ventures VII Annex Fund, L.P. | $27.94 · — to 2026-06-25 | 3,249 Common Stock | (F29) Received in exchange for a warrant to purchase 112,796 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 16 | Derivative | Warrant | 2023-03-20 | A | A | 2,203 | — | 2,203 | I By Sanderling Ventures VII (Canada), LP | $27.94 · — to 2026-03-04 | 2,203 Common Stock | (F28) Received in exchange for a warrant to purchase 76,470 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 17 | Derivative | Warrant | 2023-03-20 | A | A | 12,380 | — | 12,380 | I By Sanderling Ventures VII (Canada), LP | $27.94 · — to 2026-06-25 | 12,380 Common Stock | (F27) Received in exchange for a warrant to purchase 429,837 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 18 | Derivative | Warrant | 2023-03-20 | A | A | 8,393 | — | 8,393 | I By Sanderling Ventures VII, LP | $27.94 · — to 2026-02-22 | 8,393 Common Stock | (F26) Received in exchange for a warrant to purchase 291,407 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 19 | Derivative | Warrant | 2023-03-20 | A | A | 183 | — | 183 | I By Sanderling Ventures VII, LP | $27.94 · — to 2026-06-25 | 183 Common Stock | (F25) Received in exchange for a warrant to purchase 6,343 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 20 | Derivative | Warrant | 2023-03-20 | A | A | 237 | — | 237 | I By Sanderling Ventures Management VI | $27.94 · — to 2026-03-04 | 237 Common Stock | (F24) Received in exchange for a warrant to purchase 8,203 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 21 | Derivative | Warrant | 2023-03-20 | A | A | 167 | — | 167 | I | $27.94 · — to 2026-06-25 | 167 Common Stock | (F33) Received in exchange for a warrant to purchase 5,775 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F16) Immediately exercisable. |
| 22 | Derivative | Warrant | 2023-03-20 | A | A | 2,672 | — | 2,672 | I By Sanderling Venture Partners VI, LP | $26.74 · — to 2027-02-28 | 2,672 Common Stock | (F18) Received in exchange for a warrant to purchase 92,748 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 23 | Derivative | Warrant | 2023-03-20 | A | A | 16,539 | — | 16,539 | I By Sanderling Venture Partners VI, LP | $27.94 · — to 2026-02-22 | 16,539 Common Stock | (F19) Received in exchange for a warrant to purchase 574,296 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 24 | Derivative | Warrant | 2023-03-20 | A | A | 2,685 | — | 2,685 | I By Sanderling Venture Partners VI Co-Investment Fund, L.P. | $27.94 · — to 2026-06-25 | 2,685 Common Stock | (F20) Received in exchange for a warrant to purchase 93,225 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 25 | Derivative | Warrant | 2023-03-20 | A | A | 1,910 | — | 1,910 | I By Sanderling Venture Partners VI Co-Investment Fund, L.P. | $26.74 · — to 2027-02-28 | 1,910 Common Stock | (F21) Received in exchange for a warrant to purchase 66,305 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 26 | Derivative | Warrant | 2023-03-20 | A | A | 6,852 | — | 6,852 | I By Sanderling Venture Partners VI Co-Investment Fund, L.P. | $27.94 · — to 2026-02-22 | 6,852 Common Stock | (F22) Received in exchange for a warrant to purchase 237,911 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |
| 27 | Derivative | Warrant | 2023-03-20 | A | A | 15,403 | — | 15,403 | I By Sanderling Ventures Management VI | $27.94 · — to 2026-06-25 | 15,403 Common Stock | (F23) Received in exchange for a warrant to purchase 534,815 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F16) Immediately exercisable. |